Neurogene Inc.

NGNE

Neurogene Inc.

NGNE

Insider Sentiment (TTM):

Last Purchase:2024-11-26Last Sale:2026-05-06Shares Purchased (TTM):0Shares Sold (TTM):31,980

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:16,904,583Shares Outstanding:22,305,734Institutional Ownership Pct.:75.79%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Series A2 Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	-
Series B Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	-
Cash And Cash Equivalents At Carrying Value	112	124	104	71	59	71	137	67	111	150	148	25
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	-	-	-	-	-	53
Other Assets Current	-	-	-	-	-	-	-	-	-	-	-	1
Common Class A	-	-	-	-	-	-	-	-	-	-	0	-
Short Term Investments	113	119	165	194	216	222	176	72	43	19	49	-
Common Class B	-	-	-	-	-	-	-	-	-	-	0	-
Prepaid Expense And Other Assets Current	4	4	3	5	4	4	4	5	5	5	3	-
Assets Current	229	247	272	271	279	296	316	144	159	174	200	80
Property Plant And Equipment Net	12	13	13	13	14	15	15	16	16	16	17	0
Operating Lease Right Of Use Asset	2	2	3	2	3	3	3	3	3	4	4	9
Finance Lease Right Of Use Asset	-	0	0	0	0	0	0	0	0	0	0	-
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	1	-
Other Assets Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Assets	244	263	289	288	297	315	336	164	180	195	223	90
Liabilities
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	-	-	-	-	-	-	-	-	-	-	-	4
Liabilities Current
Accounts Payable Current	3	5	2	2	2	3	1	2	2	2	3	-
Accrued Liabilities Current	15	11	11	9	9	7	10	10	7	7	17	-
Operating Lease Liability Current	3	3	3	3	3	3	3	3	3	3	3	2
Finance Lease Liability Current	-	0	0	0	0	0	0	0	0	0	0	0
Asset Acquisition Contingent Consideration Liabili…	0	0	1	1	1	1	1	1	1	0	0	-
Liabilities Current	22	19	16	15	15	14	15	16	13	12	23	5
Operating Lease Liability Noncurrent	5	6	7	7	8	9	9	10	11	12	12	9
Finance Lease Liability Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Asset Acquisition Contingent Consideration Liabili…	0	0	0	0	1	1	1	1	1	1	1	-
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities	27	25	24	22	24	24	25	27	25	25	37	14
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	635	621	618	593	580	577	573	380	378	375	373	547
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	-	-	-	-	0
Retained Earnings Accumulated Deficit	-418	-384	-353	-328	-307	-285	-262	-243	-223	-204	-187	-472
Stockholders Equity	217	238	265	266	273	292	310	137	155	171	186	-183
Liabilities And Stockholders Equity	244	263	289	288	297	315	336	164	180	195	223	90
Temporary Equity
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	-	-	-	-	0	-
Preferred Stock Shares Authorized	50	50	50	50	50	50	50	50	50	50	50	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	450	450	450	450	450	450	450	450	450	450	450	20
Common Stock Shares Issued	16	16	15	15	14	15	15	13	13	13	7	9
Shares Outstanding	16	16	15	15	14	15	15	13	13	13	13	9
Series A1 Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	-	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-16.01%	12.05%	6.53%	-	-	-	-	-	-	-	-	-
2025	15.48%	9.71%	54.24%	-1.97%	9.78%	68.35%	-23.44%	-23.90%	-33.33%	33.25%	42.68%	39.23%
2024	15.69%	11.97%	37.94%	5.14%	13.32%	35.91%	18.62%	-1.21%	3.23%	-17.69%	28.87%	41.55%
2023	-	-	-	-	-	-	1.29%	63.93%	121.21%	5.73%	-13.45%	0.88%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.64	13.08	16.56	18.39	18.07	21.03	20.84	9.09	12.17	14.74	8.72	15.33
Quick Ratio	10.48	12.89	16.39	18.04	17.78	20.76	20.61	8.80	11.77	14.35	8.58	15.33
Working Capital	207.41M	227.88M	255.36M	255.81M	263.55M	282.30M	300.77M	127.85M	146.08M	162.32M	177.38M	74.68M
Leverage & Debt
Debt to Equity	0.13	0.11	0.09	0.08	0.09	0.08	0.08	0.19	0.16	0.14	0.20	-0.08
Interest Coverage TTM	-60,673.50	-36,919.33	-20,665.60	-16,218.33	-11,961.50	-8,158.64	-6,883.75	-5,055.07	-4,304.06	-4,088.47	-3,970.21	-63.66
Debt Ratio	0.11	0.10	0.08	0.08	0.08	0.07	0.08	0.16	0.14	0.13	0.16	0.16
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-4.93	-4.42	-4.24	-4.02	-4.01	-3.85	-4.28	-3.14	-2.81	-2.42	-7.80	-111.55
Free Cash Flow Per Share TTM	-3.89	-3.73	-3.67	-3.70	-3.54	-3.39	-4.07	-4.18	-3.94	-3.54	-105.20	-121.05
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-9,702.16%	-8,930.27%	-8,197.41%	-7,444.86%	-	-	-
Net Profit Margin TTM	-	-	-	-	-	-8,742.70%	-8,123.68%	-5,756.43%	-5,146.70%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-	-100.00%	-100.00%	-100.00%	-100.00%	-	-	-	-	-	-	-
Net Income Growth (1Y)	31.66%	21.97%	20.24%	59.88%	77.27%	97.36%	106.91%	6.97%	-1.38%	-21.35%	-34.20%	-16.03%
EPS Growth (1Y)	22.92%	14.81%	-0.96%	28.04%	42.64%	58.89%	-94.21%	-97.18%	-97.41%	-97.98%	-47.22%	1,979.37%
Valuation Metrics
P/E TTM	-6.38	-4.56	-4.86	-4.31	-3.73	-3.04	-5.34	-13.36	-12.95	-21.00	-0.26	-0.14
P/B TTM	3.27	1.89	1.66	1.38	1.15	0.84	1.29	5.18	3.98	5.04	0.05	-0.04
P/S TTM	-	-	-	-	-	265.80	434.14	769.04	666.49	-	-	-
Market Cap	709.26M	449.68M	439.32M	366.85M	314.78M	245.87M	401.58M	711.37M	616.50M	860.40M	9.53M	7.05M
Enterprise Value	596.44M	325.20M	335.16M	295.54M	255.68M	174.82M	264.74M	644.49M	505.24M	710.02M	34.08M	-38.50M
Calculated Values
Free Cash Flow TTM	-87.71M	-83.20M	-78.36M	-78.41M	-74.51M	-71.25M	-71.41M	-70.90M	-66.82M	-59.87M	-51.74M	-54.02M
Net Debt	-112.82M	-124.49M	-104.17M	-71.31M	-59.10M	-71.05M	-136.85M	-66.88M	-111.27M	-150.38M	24.55M	-45.55M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-06Sale

Owner: Cvijic, Christine Mikail

Title: President and CFO

Shares: 9,600

Price/Share: $31.26

Value: $300,096.00

Shares Owned: 93,640

Relationship: Director,Officer

Ownership: Direct

2026-03-26Sale

Owner: Mcminn, Rachel

Title: Chief Executive Officer

Shares: 3,352

Price/Share: $22.07

Value: $73,978.64

Shares Owned: 1,344,307

Relationship: Director,Officer

Ownership: Direct

2026-03-26Sale

Owner: Jordan, Julie

Title: Chief Medical Officer

Shares: 828

Price/Share: $21.89

Value: $18,124.92

Shares Owned: 12,472

Relationship: Officer

Ownership: Direct

2026-03-26Sale

Owner: Cvijic, Christine Mikail

Title: President and CFO

Shares: 2,558

Price/Share: $21.62

Value: $55,303.96

Shares Owned: 103,240

Relationship: Officer

Ownership: Direct

2026-03-13Sale

Owner: Cobb, Stuart

Title: Chief Scientific Officer

Shares: 6,797

Price/Share: $21.28

Value: $144,640.16

Shares Owned: 30,497

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-06	Cvijic, Christine Mikail	Director,Officer	President and CFO	Direct	Sale	9,600	31.26	$300,096.00	93,640	4
2026-03-26	Mcminn, Rachel	Director,Officer	Chief Executive Officer	Direct	Sale	3,352	22.07	$73,978.64	1,344,307	4
2026-03-26	Jordan, Julie	Officer	Chief Medical Officer	Direct	Sale	828	21.89	$18,124.92	12,472	4
2026-03-26	Cvijic, Christine Mikail	Officer	President and CFO	Direct	Sale	2,558	21.62	$55,303.96	103,240	4
2026-03-13	Cobb, Stuart	Officer	Chief Scientific Officer	Direct	Sale	6,797	21.28	$144,640.16	30,497	4
2026-03-13	Cvijic, Christine Mikail	Officer	President and CFO	Direct	Sale	4,045	21.23	$85,875.35	105,798	4
2026-02-27	Cvijic, Christine Mikail	Officer	President and CFO	Direct	Sale	4,800	25.11	$120,528.00	109,843	4
2025-05-14	Cobb, Stuart	Officer	Chief Scientific Officer	Direct	Sale	6,797	15.15	$102,974.55	20,794	4
2025-03-13	Cvijic, Christine Mikail	Officer	President and CFO	Direct	Sale	4,501	16.94	$76,246.94	72,343	4
2024-11-26	Akkaraju, Srinivas, Samsa…	TenPercentOwner	-	Indirect	Purchase	48,770	26.29	$1,282,163.30	1,717,127	4
2024-11-22	Cvijic, Christine Mikail	Officer	President and CFO	Direct	Purchase	24,000	20.48	$491,520.00	76,844	4
2024-11-22	Mcminn, Rachel	Director,Officer	Chief Executive Officer	Direct	Purchase	47,500	20.40	$969,000.00	1,297,859	4
2023-08-17	Baker, Brothers Life Scie…	Director,TenPercentOwner	-	Indirect	Purchase	166,942	0.69	$115,189.98	5,612,949	4
2023-08-11	Smith, Sean Michael	Officer	Interim CFO, Prin Acct Off	Direct	Sale	1,323	0.62	$820.26	21,637	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

75.79%

Inst. Shares: 16,904,583

Shares Outstanding: 22,305,734

2025-12-31

77.38%

Inst. Shares: 16,502,774

Shares Outstanding: 21,326,283

2025-09-30

72.26%

Inst. Shares: 15,297,040

Shares Outstanding: 21,168,431

2025-06-30

72.87%

Inst. Shares: 15,342,454

Shares Outstanding: 21,055,378

2025-03-31

76.84%

Inst. Shares: 16,133,956

Shares Outstanding: 20,996,287

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	16,904,583	22,305,734	75.79%
2025-12-31	16,502,774	21,326,283	77.38%
2025-09-30	15,297,040	21,168,431	72.26%
2025-06-30	15,342,454	21,055,378	72.87%
2025-03-31	16,133,956	20,996,287	76.84%
2024-12-31	15,923,234	17,567,082	90.64%
2024-09-30	13,824,242	16,953,443	81.54%
2024-06-30	13,257,436	16,941,524	78.25%
2024-03-31	12,049,448	16,903,735	71.28%
2023-12-31	9,143,435	491,867	-
2023-09-30	3,486,093	446,255	-
2023-06-30	16,464,752	444,465	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Neurogene Inc. (NGNE) — SEC Financial Statements & Analysis

Neurogene Inc. (NGNE) is a pharmaceutical preparations company. Neurogene Inc. trades on Nasdaq as: NGNE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Neurogene Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.13x, a Price-to-Sales (P/S) ratio of 265.80x (TTM), a Price-to-Book (P/B) ratio of 3.27x (TTM), at a market cap of $709.26M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.13x
P/S TTM: 265.80x
P/B TTM: 3.27x
Market Cap: $709.26M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Neurogene Inc. in?

Neurogene Inc. (NGNE) operates in the Pharmaceutical Preparations industry.

What is NGNE's market cap?

Neurogene Inc. (NGNE) has a market capitalization of $709.26M as of 2026-06-30.

What exchange does NGNE trade on?

Neurogene Inc. (NGNE) trades on the Nasdaq.

Neurogene Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Neurogene Inc. (NGNE) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Neurogene Inc. (NGNE) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.